Table 3. Genotypic differences between the patients with pachychoroid neovasculopathy and neovascular AMD.
| Data from | n | ARMS2 A69S (rs10490924) |
CFH I62V (rs800292) |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GG | GT | TT | >T-allele frequency | P* | Odds ratio (vs control) | AA | AG | GG | A-allele frequency | P* | |||
| Normal (Japanese) | Nagahama study | 3,248 | 1312 | 1499 | 435 | 36.5% | – | – | 546 | 1538 | 1162 | 40.5% | − |
| Pachychoroid neovasculopathy | Current study | 39 | 11 | 16 | 12 | 51.3% | 0.029 | 1.83† | 8 | 16 | 15 | 41.0% | 0.013 |
| Neovascular AMD | Current study | 161 | 24 | 64 | 71 | 64.8% | 3.20† | 17 | 48 | 96 | 25.5% | ||
| Neovascular AMD (Japanese) | Arakawa et al. | 1,536 | – | – | – | 57.4% | – | 2.41‡ | – | – | – | 27.1% | – |
| Neovascular AMD (Caucasian) | Sobrin et al. | 1,775 | – | – | – | – | – | 3.67‡ | – | – | – | – | – |
*Adjusting for age and sex.
†Compared to 3,248 normal Japanese.
‡Cited from the original paper.
CSC: central serous chorioretinopathy, AMD: age-related macular degeneration, CNV: choroidal neovascularization.